SR
MDLN

Syntax Research’s Medline Inc MDLN Stock Holding History

Syntax Research’s Portfolio MDLN Stock Details MDLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.7K Buy
+2,250
New +$90.7K 0.06% 76

Other funds holding MDLN

CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
HFCIX
H&F Corporate Investors X San Francisco, California $2.8B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Syntax Research's MDLN Position: Q2 2026 in Review

Syntax Research opened a new position in Medline Inc (MDLN) in Q2 2026: 2,250 shares worth $88.7K. The stake represents 0.06% of the portfolio and ranks #76 among its holdings.

405 funds tracked by Wall St. Rank hold MDLN as of Q2 2026.

  • Syntax Research held 2,250 shares of Medline Inc worth $88.7K as of Q2 2026.
  • Medline Inc was a new Syntax Research position in Q2 2026.
  • Medline Inc made up 0.06% of Syntax Research's portfolio in Q2 2026, its #76 holding.
  • 405 funds tracked by Wall St. Rank held Medline Inc as of Q2 2026.

Based on Syntax Research's 13F filing for Q2 2026, filed 31 Jul 2026.